BioSpace News Archive

VETIGENICS, an animal health biotechnology company, announced that it is extending its discovery collaboration with Merck Animal Health, a division of Merck & Co., Inc. for use of the VETIGENICS CANIBODY™ Platform to discover and develop novel therapeutic antibodies to treat chronic diseases of companion animals.

Biolinq Incorporated, a medical device company developing a continuous glucose sensor with a novel integrated display on its wearable device, has announced the closing of a $100 million Series B financing round led by RiverVest Venture Partners.

Immunicom, Inc. recently co-hosted an international oncology meeting with Acibadem Healthcare Group at Acibadem University Hospital in Istanbul, Turkey.

Renew Bioscience announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Cerezen ® Device, a novel treatment for Mild Cognitive Impairment due to Alzheimer’s Disease (MCI) and mild dementia of the Alzheimer’s treatment

Pinnacle Clinical Research, PLLC is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid but have not achieved the recommended treatment goal or cannot tolerate UDCA.

Bristol Myers Squibb Canada announces two recent Health Canada approvals for OPDIVO®.

Agile Therapeutics, Inc., a women’s healthcare company, reported financial results for the three months ended September 30, 2021 and provided a corporate update.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021

Surgery Partners, Inc., a leading provider of surgical services, announced results for the third quarter ended September 30, 2021.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update on eganelisib, its potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic.